{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:33:16Z","timestamp":1793118796002,"version":"4.5.0"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2022YFS0610"],"award-info":[{"award-number":["2022YFS0610"]}]},{"name":"Luzhou Municipal People\u2019s Government - Southwest Medical University Science and Technology Strategic Cooperation","award":["2021LZXNYD-J33"],"award-info":[{"award-number":["2021LZXNYD-J33"]}]},{"name":"Hejiang People's Hospital - Southwest Medical University Science and Technology Strategic Cooperation Project","award":["2021HJXNYD13"],"award-info":[{"award-number":["2021HJXNYD13"]}]},{"name":"Gulin County People's Hospital - Affiliated Hospital of Southwest Medical University Science and Technology strategic Cooperation","award":["2022GLXNYDFY13"],"award-info":[{"award-number":["2022GLXNYDFY13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, microcirculation, mitochondrial function, fibrosis, oxidative stress, endoplasmic reticulum stress, programmed cell death, autophagy, and the intestinal flora, which are involved in diabetic cardiomyopathy. This review summarizes the current knowledge of the mechanisms of SGLT2i for the treatment of diabetic cardiomyopathy.<\/jats:p><jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12933-023-01816-5","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T19:03:05Z","timestamp":1681412585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms"],"prefix":"10.1186","volume":"22","author":[{"given":"Keming","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"1816_CR1","first-page":"373","volume":"23","author":"AM Ahmed","year":"2002","unstructured":"Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002;23:373\u20138.","journal-title":"Saudi Med J"},{"key":"1816_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88\u201398.","journal-title":"Nat Rev Endocrinol"},{"key":"1816_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61:21\u20138.","journal-title":"Diabetologia"},{"key":"1816_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-013-9377-8","volume":"19","author":"M Isfort","year":"2014","unstructured":"Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2014;19:35\u201348.","journal-title":"Heart Fail Rev"},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660\u201371.","journal-title":"Diabetologia"},{"key":"1816_CR6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/ijms17122136","volume":"17","author":"ME Holscher","year":"2016","unstructured":"Holscher ME, Bode C, Bugger H. Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci. 2016;17:2136.","journal-title":"Int J Mol Sci"},{"key":"1816_CR7","doi-asserted-by":"publisher","first-page":"e001313","DOI":"10.1136\/bmjdrc-2020-001313","volume":"9","author":"OS Reifsnider","year":"2021","unstructured":"Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021;9:e001313.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18:20.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.511.S14-9","author":"M Isaji","year":"2011","unstructured":"Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl. 2011. https:\/\/doi.org\/10.1038\/ki.2010.511.S14-9.","journal-title":"Kidney Int Suppl"},{"key":"1816_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases8020014","volume":"8","author":"Y Saisho","year":"2020","unstructured":"Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8:14.","journal-title":"Diseases"},{"key":"1816_CR11","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142:1712\u201322.","journal-title":"Int J Cancer"},{"key":"1816_CR12","doi-asserted-by":"publisher","first-page":"102637","DOI":"10.1016\/j.ebiom.2020.102637","volume":"52","author":"Y Lin","year":"2020","unstructured":"Lin Y, Nan J, Shen J, Lv X, Chen X, Lu X, et al. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells. EBioMedicine. 2020;52:102637.","journal-title":"EBioMedicine"},{"key":"1816_CR13","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","volume":"42","author":"H Kondo","year":"2021","unstructured":"Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42:4947\u201360.","journal-title":"Eur Heart J"},{"key":"1816_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, et al. Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 2018;9:1575.","journal-title":"Front Physiol"},{"key":"1816_CR15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, et al. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143:2188\u2013204.","journal-title":"Circulation"},{"key":"1816_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1479164115580936","volume":"12","author":"N Amaral","year":"2015","unstructured":"Amaral N, Okonko DO. Metabolic abnormalities of the heart in type II diabetes. Diab Vasc Dis Res. 2015;12:239\u201348.","journal-title":"Diab Vasc Dis Res"},{"key":"1816_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12997\/jla.2023.12.1.47","volume":"12","author":"SAT Dakhili","year":"2023","unstructured":"Dakhili SAT, Greenwell AA, Ussher JR. Pyruvate dehydrogenase complex and glucose oxidation as a therapeutic target in diabetic heart disease. J Lipid Atheroscler. 2023;12:47\u201357.","journal-title":"J Lipid Atheroscler"},{"key":"1816_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","volume":"77","author":"Y Mizuno","year":"2017","unstructured":"Mizuno Y, Harada E, Nakagawa H, Morikawa Y, Shono M, Kugimiya F, et al. The diabetic heart utilizes ketone bodies as an energy source. Metabolism. 2017;77:65\u201372.","journal-title":"Metabolism"},{"key":"1816_CR19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00424-020-02444-8","volume":"472","author":"L Bertrand","year":"2020","unstructured":"Bertrand L, Auquier J, Renguet E, Ang\u00e9 M, Cumps J, Horman S, et al. Glucose transporters in cardiovascular system in health and disease. Pflugers Arch. 2020;472:1385\u201399.","journal-title":"Pflugers Arch"},{"key":"1816_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s00125-019-4819-z","volume":"62","author":"J Mustroph","year":"2019","unstructured":"Mustroph J, L\u00fccht CM, Wagemann O, Sowa T, Hammer KP, Sag CM, et al. Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1. Diabetologia. 2019;62:726\u20139.","journal-title":"Diabetologia"},{"key":"1816_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018;3:575\u201387.","journal-title":"JACC Basic Transl Sci"},{"key":"1816_CR22","doi-asserted-by":"publisher","first-page":"109767","DOI":"10.1016\/j.celrep.2021.109767","volume":"37","author":"A Angelini","year":"2021","unstructured":"Angelini A, Saha PK, Jain A, Jung SY, Mynatt RL, Pi X, et al. PHDs\/CPT1B\/VDAC1 axis regulates long-chain fatty acid oxidation in cardiomyocytes. Cell Rep. 2021;37:109767.","journal-title":"Cell Rep"},{"key":"1816_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1124\/jpet.118.253666","volume":"368","author":"H Oshima","year":"2019","unstructured":"Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368:524\u201334.","journal-title":"J Pharmacol Exp Ther"},{"key":"1816_CR24","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.3390\/ijms222212408","volume":"22","author":"CC Huang","year":"2021","unstructured":"Huang CC, Chou CA, Chen WY, Yang JL, Lee WC, Chen JB, et al. Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPAR\u03b3\/CD36 pathway in obese mice. Int J Mol Sci. 2021;22:12408.","journal-title":"Int J Mol Sci"},{"key":"1816_CR25","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","volume":"170","author":"A Aragon-Herrera","year":"2019","unstructured":"Aragon-Herrera A, Feijoo-Bandin S, Santiago MO, Barral L, Campos-Toimil M, Gil-Longo J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.","journal-title":"Biochem Pharmacol"},{"key":"1816_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-nutr-071812-161220","volume":"34","author":"MY Pepino","year":"2014","unstructured":"Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:281\u2013303.","journal-title":"Annu Rev Nutr"},{"key":"1816_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-020-01188-0","volume":"20","author":"L Wang","year":"2021","unstructured":"Wang L, Cai Y, Jian L, Cheung CW, Zhang L, Xia Z. Impact of peroxisome proliferator-activated receptor-\u03b1 on diabetic cardiomyopathy. Cardiovasc Diabetol. 2021;20:2.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR28","doi-asserted-by":"publisher","first-page":"117414","DOI":"10.1016\/j.lfs.2020.117414","volume":"247","author":"D Wei","year":"2020","unstructured":"Wei D, Liao L, Wang H, Zhang W, Wang T, Xu Z. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro. Life Sci. 2020;247:117414.","journal-title":"Life Sci"},{"key":"1816_CR29","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/ijms20051190","volume":"20","author":"H Yanai","year":"2019","unstructured":"Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci. 2019;20:1190.","journal-title":"Int J Mol Sci"},{"key":"1816_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1055\/a-0958-2441","volume":"51","author":"P Wu","year":"2019","unstructured":"Wu P, Wen W, Li J, Xu J, Zhao M, Chen H, et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res. 2019;51:487\u201394.","journal-title":"Horm Metab Res"},{"key":"1816_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","volume":"27","author":"RM Krauss","year":"2004","unstructured":"Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496\u2013504.","journal-title":"Diabetes Care"},{"key":"1816_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1476-511X-13-128","volume":"13","author":"L Liu","year":"2014","unstructured":"Liu L, Mu Y, Han W, Wang C. Association of hypercholesterolemia and cardiac function evaluated by speckle tracking echocardiography in a rabbit model. Lipids Health Dis. 2014;13:128.","journal-title":"Lipids Health Dis"},{"key":"1816_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/01.CIR.0000109213.10461.F6","volume":"109","author":"Y Huang","year":"2004","unstructured":"Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation. 2004;109:97\u2013102.","journal-title":"Circulation"},{"key":"1816_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/dom.13577","volume":"21","author":"JH Kim","year":"2019","unstructured":"Kim JH, Lee M, Kim SH, Kim SR, Lee BW, Kang ES, et al. Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk. Diabetes Obes Metab. 2019;21:801\u201311.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12933-021-01410-7","volume":"20","author":"R Pietschner","year":"2021","unstructured":"Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20:219.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR36","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"1816_CR37","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"1816_CR38","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1089\/ars.2015.6293","volume":"22","author":"CA Galloway","year":"2015","unstructured":"Galloway CA, Yoon Y. Mitochondrial dynamics in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22:1545\u201362.","journal-title":"Antioxid Redox Signal"},{"key":"1816_CR39","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1161\/CIRCULATIONAHA.118.033552","volume":"139","author":"S Wu","year":"2019","unstructured":"Wu S, Lu Q, Ding Y, Wu Y, Qiu Y, Wang P, et al. Hyperglycemia-driven inhibition of AMP-activated protein kinase \u03b12 induces diabetic cardiomyopathy by promoting mitochondria-associated endoplasmic reticulum membranes in vivo. Circulation. 2019;139:1913\u201336.","journal-title":"Circulation"},{"key":"1816_CR40","doi-asserted-by":"publisher","first-page":"750382","DOI":"10.3389\/fcell.2021.750382","volume":"9","author":"H Zheng","year":"2021","unstructured":"Zheng H, Zhu H, Liu X, Huang X, Huang A, Huang Y. Mitophagy in diabetic cardiomyopathy: roles and mechanisms. Front Cell Dev Biol. 2021;9:750382.","journal-title":"Front Cell Dev Biol"},{"key":"1816_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jemt.1070270303","volume":"27","author":"J Bereiter-Hahn","year":"1994","unstructured":"Bereiter-Hahn J, V\u00f6th M. Dynamics of mitochondria in living cells: shape changes, dislocations, fusion, and fission of mitochondria. Microsc Res Tech. 1994;27:198\u2013219.","journal-title":"Microsc Res Tech"},{"key":"1816_CR42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/ijms19020564","volume":"19","author":"N Zemirli","year":"2018","unstructured":"Zemirli N, Morel E, Molino D. Mitochondrial dynamics in basal and stressful conditions. Int J Mol Sci. 2018;19:564.","journal-title":"Int J Mol Sci"},{"key":"1816_CR43","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1073\/pnas.0511154103","volume":"103","author":"T Yu","year":"2006","unstructured":"Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;103:2653\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1816_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, et al. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2018;236:69\u201384.","journal-title":"J Endocrinol"},{"key":"1816_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1749-6632.2010.05629.x","volume":"1201","author":"CR Chang","year":"2010","unstructured":"Chang CR, Blackstone C. Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann N Y Acad Sci. 2010;1201:34\u20139.","journal-title":"Ann N Y Acad Sci"},{"key":"1816_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335\u201346.","journal-title":"Redox Biol"},{"key":"1816_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1042\/EBC20170104","volume":"62","author":"L Tilokani","year":"2018","unstructured":"Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem. 2018;62:341\u201360.","journal-title":"Essays Biochem"},{"key":"1816_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1083\/jcb.200211046","volume":"160","author":"H Chen","year":"2003","unstructured":"Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160:189\u2013200.","journal-title":"J Cell Biol"},{"key":"1816_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1167\/iovs.61.6.42","volume":"61","author":"S Sun","year":"2020","unstructured":"Sun S, Erchova I, Sengpiel F, Votruba M. Opa1 deficiency leads to diminished mitochondrial bioenergetics with compensatory increased mitochondrial motility. Invest Ophthalmol Vis Sci. 2020;61:42.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1816_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","volume":"17","author":"A Durak","year":"2018","unstructured":"Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018;17:144.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18:165.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1042\/bse0470069","volume":"47","author":"FR Jornayvaz","year":"2010","unstructured":"Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem. 2010;47:69\u201384.","journal-title":"Essays Biochem"},{"key":"1816_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bbamcr.2010.09.019","volume":"1813","author":"RC Scarpulla","year":"2011","unstructured":"Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813:1269\u201378.","journal-title":"Biochim Biophys Acta"},{"key":"1816_CR54","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1073\/pnas.91.4.1309","volume":"91","author":"JV Virbasius","year":"1994","unstructured":"Virbasius JV, Scarpulla RC. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. Proc Natl Acad Sci USA. 1994;91:1309\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1816_CR55","doi-asserted-by":"publisher","first-page":"C1669","DOI":"10.1152\/ajpcell.00409.2002","volume":"284","author":"I Irrcher","year":"2003","unstructured":"Irrcher I, Adhihetty PJ, Sheehan T, Joseph AM, Hood DA. PPARgamma coactivator-1alpha expression during thyroid hormone- and contractile activity-induced mitochondrial adaptations. Am J Physiol Cell Physiol. 2003;284:C1669\u201377.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1816_CR56","doi-asserted-by":"publisher","first-page":"H54","DOI":"10.1152\/ajpheart.00845.2013","volume":"307","author":"TL Croston","year":"2014","unstructured":"Croston TL, Thapa D, Holden AA, Tveter KJ, Lewis SE, Shepherd DL, et al. Functional deficiencies of subsarcolemmal mitochondria in the type 2 diabetic human heart. Am J Physiol Heart Circ Physiol. 2014;307:H54-65.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1816_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41419-018-0273-y","volume":"9","author":"PF Secker","year":"2018","unstructured":"Secker PF, Beneke S, Schlichenmaier N, Delp J, Gutbier S, Leist M, et al. Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis. 2018;9:226.","journal-title":"Cell Death Dis"},{"key":"1816_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1074\/jbc.M808518200","volume":"284","author":"Y Hu","year":"2009","unstructured":"Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, Trauger SA, et al. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem. 2009;284:547\u201355.","journal-title":"J Biol Chem"},{"key":"1816_CR59","doi-asserted-by":"publisher","first-page":"F1017","DOI":"10.1152\/ajprenal.00021.2020","volume":"318","author":"J Hodrea","year":"2020","unstructured":"Hodrea J, Balogh DB, Hosszu A, Lenart L, Besztercei B, Koszegi S, et al. Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney. Am J Physiol Renal Physiol. 2020;318:F1017\u201329.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1816_CR60","doi-asserted-by":"publisher","first-page":"7839101","DOI":"10.1155\/2017\/7839101","volume":"2017","author":"D Huang","year":"2017","unstructured":"Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi KC. Macrovascular complications in patients with diabetes and prediabetes. Biomed Res Int. 2017;2017:7839101.","journal-title":"Biomed Res Int"},{"key":"1816_CR61","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1177\/0300060516675504","volume":"45","author":"A Kibel","year":"2017","unstructured":"Kibel A, Selthofer-Relatic K, Drenjancevic I, Bacun T, Bosnjak I, Kibel D, et al. Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res. 2017;45:1901\u201329.","journal-title":"J Int Med Res"},{"key":"1816_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fca-2018-0045","volume":"14","author":"RJ Henning","year":"2018","unstructured":"Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14:491\u2013509.","journal-title":"Future Cardiol"},{"key":"1816_CR63","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.3390\/cells11193034","volume":"11","author":"AV Poznyak","year":"2022","unstructured":"Poznyak AV, Litvinova L, Poggio P, Sukhorukov VN, Orekhov AN. Effect of glucose levels on cardiovascular risk. Cells. 2022;11:3034.","journal-title":"Cells"},{"key":"1816_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.120.14686","volume":"76","author":"SJ Forrester","year":"2020","unstructured":"Forrester SJ, Preston KJ, Cooper HA, Boyer MJ, Escoto KM, Poltronetti AJ, et al. Mitochondrial fission mediates endothelial inflammation. Hypertension. 2020;76:267\u201376.","journal-title":"Hypertension"},{"key":"1816_CR65","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr","year":"2016","unstructured":"Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620\u201336.","journal-title":"Circ Res"},{"key":"1816_CR66","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/db16-0915","volume":"66","author":"Q Wang","year":"2017","unstructured":"Wang Q, Zhang M, Torres G, Wu S, Ouyang C, Xie Z, et al. Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of Drp1-mediated mitochondrial fission. Diabetes. 2017;66:193\u2013205.","journal-title":"Diabetes"},{"key":"1816_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11883-020-00870-8","volume":"22","author":"K Tian","year":"2020","unstructured":"Tian K, Xu Y, Sahebkar A, Xu S. CD36 in atherosclerosis: pathophysiological mechanisms and therapeutic implications. Curr Atheroscler Rep. 2020;22:59.","journal-title":"Curr Atheroscler Rep"},{"key":"1816_CR68","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/cells12040522","volume":"12","author":"AV Blagov","year":"2023","unstructured":"Blagov AV, Markin AM, Bogatyreva AI, Tolstik TV, Sukhorukov VN, Orekhov AN. The role of macrophages in the pathogenesis of atherosclerosis. Cells. 2023;12:522.","journal-title":"Cells"},{"key":"1816_CR69","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1038\/s41598-019-54224-9","volume":"9","author":"J Pennig","year":"2019","unstructured":"Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, F\u00fcner L, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep. 2019;9:17937.","journal-title":"Sci Rep"},{"key":"1816_CR70","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"CN Koyani","year":"2020","unstructured":"Koyani CN, Plastira I, Sourij H, Hallstrom S, Schmidt A, Rainer PP, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. 2020;158:104870.","journal-title":"Pharmacol Res"},{"key":"1816_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cbf.1467","volume":"26","author":"H Shan","year":"2008","unstructured":"Shan H, Bai X, Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases. Cell Biochem Funct. 2008;26:459\u201366.","journal-title":"Cell Biochem Funct"},{"key":"1816_CR72","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/jcmm.14233","volume":"24","author":"S Khemais-Benkhiat","year":"2020","unstructured":"Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, Park SH, Amoura L, Abbas M, et al. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med. 2020;24:2109\u201322.","journal-title":"J Cell Mol Med"},{"key":"1816_CR73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1474-9726.2006.00199.x","volume":"5","author":"BY Lee","year":"2006","unstructured":"Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5:187\u201395.","journal-title":"Aging Cell"},{"key":"1816_CR74","doi-asserted-by":"publisher","first-page":"e56864","DOI":"10.1371\/journal.pone.0056864","volume":"8","author":"Q Lv","year":"2013","unstructured":"Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE. 2013;8:e56864.","journal-title":"PLoS ONE"},{"key":"1816_CR75","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.2174\/1381612811319270016","volume":"19","author":"N Katsiki","year":"2013","unstructured":"Katsiki N, Papanas N, Fonseca VA, Maltezos E, Mikhailidis DP. Uric acid and diabetes: is there a link? Curr Pharm Des. 2013;19:4930\u20137.","journal-title":"Curr Pharm Des"},{"key":"1816_CR76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S232033","volume":"16","author":"A Albu","year":"2020","unstructured":"Albu A, Para I, Porojan M. Uric acid and arterial stiffness. Ther Clin Risk Manag. 2020;16:39\u201354.","journal-title":"Ther Clin Risk Manag"},{"key":"1816_CR77","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391\u2013404.","journal-title":"Biopharm Drug Dispos"},{"key":"1816_CR78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11892-017-0869-0","volume":"17","author":"AS Shah","year":"2017","unstructured":"Shah AS, Urbina EM. Vascular and endothelial function in youth with type 2 diabetes mellitus. Curr Diab Rep. 2017;17:36.","journal-title":"Curr Diab Rep"},{"key":"1816_CR79","doi-asserted-by":"publisher","first-page":"765071","DOI":"10.3389\/fcvm.2021.765071","volume":"8","author":"E Gallinoro","year":"2021","unstructured":"Gallinoro E, Paolisso P, Candreva A, Bermpeis K, Fabbricatore D, Esposito G, et al. Microvascular dysfunction in patients with type II diabetes mellitus: invasive assessment of absolute coronary blood flow and microvascular resistance reserve. Front Cardiovasc Med. 2021;8:765071.","journal-title":"Front Cardiovasc Med"},{"key":"1816_CR80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","volume":"16","author":"F Shigiyama","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16:84.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR81","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.freeradbiomed.2011.08.011","volume":"51","author":"P Sancho","year":"2011","unstructured":"Sancho P, Martin-Sanz P, Fabregat I. Reciprocal regulation of NADPH oxidases and the cyclooxygenase-2 pathway. Free Radic Biol Med. 2011;51:1789\u201398.","journal-title":"Free Radic Biol Med"},{"key":"1816_CR82","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/153537020623100302","volume":"231","author":"N Ardanaz","year":"2006","unstructured":"Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med. 2006;231:237\u201351.","journal-title":"Exp Biol Med"},{"key":"1816_CR83","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9:e112394.","journal-title":"PLoS ONE"},{"key":"1816_CR84","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1111\/bph.13579","volume":"173","author":"E Santiago","year":"2016","unstructured":"Santiago E, Mart\u00ednez MP, Climent B, Mu\u00f1oz M, Briones AM, Salaices M, et al. Augmented oxidative stress and preserved vasoconstriction induced by hydrogen peroxide in coronary arteries in obesity: role of COX-2. Br J Pharmacol. 2016;173:3176\u201395.","journal-title":"Br J Pharmacol"},{"key":"1816_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12418","author":"R Hasan","year":"2018","unstructured":"Hasan R, Jaggar JH. KV channel trafficking and control of vascular tone. Microcirculation. 2018. https:\/\/doi.org\/10.1111\/micc.12418.","journal-title":"Microcirculation"},{"key":"1816_CR86","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","volume":"197","author":"H Li","year":"2018","unstructured":"Li H, Shin SE, Seo MS, An JR, Choi IW, Jung WK, et al. The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. Life Sci. 2018;197:46\u201355.","journal-title":"Life Sci"},{"key":"1816_CR87","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pbiomolbio.2009.10.001","volume":"103","author":"EA Ko","year":"2010","unstructured":"Ko EA, Park WS, Firth AL, Kim N, Yuan JX, Han J. Pathophysiology of voltage-gated K+ channels in vascular smooth muscle cells: modulation by protein kinases. Prog Biophys Mol Biol. 2010;103:95\u2013101.","journal-title":"Prog Biophys Mol Biol"},{"key":"1816_CR88","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcb.26174","volume":"119","author":"MSH Akash","year":"2018","unstructured":"Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119:105\u201310.","journal-title":"J Cell Biochem"},{"key":"1816_CR89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem. 2019;53:865\u201386.","journal-title":"Cell Physiol Biochem"},{"key":"1816_CR90","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, G\u00f6pel SO, Gr\u00f6nros J, Behrendt M, Sotak M, Miliotis T, et al. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(\u2013\/\u2013) mice. Cardiovasc Diabetol. 2019;18:16.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR91","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61:722\u20136.","journal-title":"Diabetologia"},{"key":"1816_CR92","doi-asserted-by":"publisher","first-page":"H585","DOI":"10.1152\/ajpheart.00821.2013","volume":"306","author":"H Zeng","year":"2014","unstructured":"Zeng H, He X, Hou X, Li L, Chen JX. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol. 2014;306:H585\u201397.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1816_CR93","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/cvr\/cvw235","volume":"113","author":"S Rawal","year":"2017","unstructured":"Rawal S, Munasinghe PE, Shindikar A, Paulin J, Cameron V, Manning P, et al. Down-regulation of proangiogenic microRNA-126 and microRNA-132 are early modulators of diabetic cardiac microangiopathy. Cardiovasc Res. 2017;113:90\u2013101.","journal-title":"Cardiovasc Res"},{"key":"1816_CR94","doi-asserted-by":"publisher","first-page":"860","DOI":"10.4239\/wjd.v5.i6.860","volume":"5","author":"J Zhao","year":"2014","unstructured":"Zhao J, Randive R, Stewart JA. Molecular mechanisms of AGE\/RAGE-mediated fibrosis in the diabetic heart. World J Diabetes. 2014;5:860\u20137.","journal-title":"World J Diabetes"},{"key":"1816_CR95","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1139\/cjpp-2013-0490","volume":"92","author":"PE Shamhart","year":"2014","unstructured":"Shamhart PE, Luther DJ, Adapala RK, Bryant JE, Petersen KA, Meszaros JG, et al. Hyperglycemia enhances function and differentiation of adult rat cardiac fibroblasts. Can J Physiol Pharmacol. 2014;92:598\u2013604.","journal-title":"Can J Physiol Pharmacol"},{"key":"1816_CR96","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ggi.12499","volume":"16","author":"M Fang","year":"2016","unstructured":"Fang M, Wang J, Li S, Guo Y. Advanced glycation end-products accelerate the cardiac aging process through the receptor for advanced glycation end-products\/transforming growth factor-\u03b2-Smad signaling pathway in cardiac fibroblasts. Geriatr Gerontol Int. 2016;16:522\u20137.","journal-title":"Geriatr Gerontol Int"},{"key":"1816_CR97","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.3390\/ijms20092164","volume":"20","author":"S Gallo","year":"2019","unstructured":"Gallo S, Vitacolonna A, Bonzano A, Comoglio P, Crepaldi T. ERK: a key player in the pathophysiology of cardiac hypertrophy. Int J Mol Sci. 2019;20:2164.","journal-title":"Int J Mol Sci"},{"key":"1816_CR98","doi-asserted-by":"publisher","first-page":"101989","DOI":"10.1016\/j.jbc.2022.101989","volume":"298","author":"X Zhong","year":"2022","unstructured":"Zhong X, Wang T, Zhang W, Wang M, Xie Y, Dai L, et al. ERK\/RSK-mediated phosphorylation of Y-box binding protein-1 aggravates diabetic cardiomyopathy by suppressing its interaction with deubiquitinase OTUB1. J Biol Chem. 2022;298:101989.","journal-title":"J Biol Chem"},{"key":"1816_CR99","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47:686\u201392.","journal-title":"Horm Metab Res"},{"key":"1816_CR100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1369\/0022155415627681","volume":"64","author":"F Xu","year":"2016","unstructured":"Xu F, Liu C, Zhou D, Zhang L. TGF-\u03b2\/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem. 2016;64:157\u201367.","journal-title":"J Histochem Cytochem"},{"key":"1816_CR101","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/978-981-13-8871-2_16","volume":"1165","author":"TT Ma","year":"2019","unstructured":"Ma TT, Meng XM. TGF-\u03b2\/Smad and renal fibrosis. Adv Exp Med Biol. 2019;1165:347\u201364.","journal-title":"Adv Exp Med Biol"},{"key":"1816_CR102","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR103","doi-asserted-by":"publisher","first-page":"105575","DOI":"10.1016\/j.intimp.2019.04.022","volume":"74","author":"R Gao","year":"2019","unstructured":"Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74:105575.","journal-title":"Int Immunopharmacol"},{"key":"1816_CR104","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fimmu.2020.00883","volume":"11","author":"AAA Alyaseer","year":"2020","unstructured":"Alyaseer AAA, de Lima MHS, Braga TT. The role of NLRP3 inflammasome activation in the epithelial to mesenchymal transition process during the fibrosis. Front Immunol. 2020;11:883.","journal-title":"Front Immunol"},{"key":"1816_CR105","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.amjcard.2007.02.080","volume":"100","author":"SP Marso","year":"2007","unstructured":"Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD trial). Am J Cardiol. 2007;100:206\u201310.","journal-title":"Am J Cardiol"},{"key":"1816_CR106","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00395-017-0622-5","volume":"112","author":"M Jung","year":"2017","unstructured":"Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchanskiy A, Garrett MR, et al. IL-10 improves cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. Basic Res Cardiol. 2017;112:33.","journal-title":"Basic Res Cardiol"},{"key":"1816_CR107","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbrc.2021.04.088","volume":"560","author":"W Li","year":"2021","unstructured":"Li W, Chi N, Rathnayake RAC, Wang R. Distinctive roles of fibrillar collagen I and collagen III in mediating fibroblast-matrix interaction: a nanoscopic study. Biochem Biophys Res Commun. 2021;560:66\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"1816_CR108","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"key":"1816_CR109","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"1816_CR110","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","volume":"126","author":"L van Heerebeek","year":"2012","unstructured":"van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830\u20139.","journal-title":"Circulation"},{"key":"1816_CR111","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCRESAHA.108.184408","volume":"104","author":"M Kr\u00fcger","year":"2009","unstructured":"Kr\u00fcger M, K\u00f6tter S, Gr\u00fctzner A, Lang P, Andresen C, Redfield MM, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87\u201394.","journal-title":"Circ Res"},{"key":"1816_CR112","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, Lodi M, Herwig M, Carrizzo A, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117:495\u2013507.","journal-title":"Cardiovasc Res"},{"key":"1816_CR113","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kovacs A, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"1816_CR114","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1002\/jcb.26097","volume":"118","author":"K Rehman","year":"2017","unstructured":"Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem. 2017;118:3577\u201385.","journal-title":"J Cell Biochem"},{"key":"1816_CR115","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/978-1-4614-5441-0_21","volume":"771","author":"K Stadler","year":"2012","unstructured":"Stadler K. Oxidative stress in diabetes. Adv Exp Med Biol. 2012;771:272\u201387.","journal-title":"Adv Exp Med Biol"},{"key":"1816_CR116","doi-asserted-by":"publisher","DOI":"10.2640\/jpp.2019.6.01","author":"K Luc","year":"2019","unstructured":"Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019. https:\/\/doi.org\/10.2640\/jpp.2019.6.01.","journal-title":"J Physiol Pharmacol"},{"key":"1816_CR117","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/ijms20010187","volume":"20","author":"A Daiber","year":"2019","unstructured":"Daiber A, Xia N, Steven S, Oelze M, Hanf A, Kroller-Schon S, et al. New therapeutic implications of endothelial nitric oxide synthase (eNOS) function\/dysfunction in cardiovascular disease. Int J Mol Sci. 2019;20:187.","journal-title":"Int J Mol Sci"},{"key":"1816_CR118","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.2174\/13816128113196660748","volume":"20","author":"S Karbach","year":"2014","unstructured":"Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A. eNOS uncoupling in cardiovascular diseases\u2013the role of oxidative stress and inflammation. Curr Pharm Des. 2014;20:3579\u201394.","journal-title":"Curr Pharm Des"},{"key":"1816_CR119","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1038\/s41598-020-71449-1","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan R, Lasker S, Hasan A, Zerin F, Zamila M, Chowdhury FI, et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci Rep. 2020;10:14459.","journal-title":"Sci Rep"},{"key":"1816_CR120","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.1038\/s41598-020-71599-2","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan R, Lasker S, Hasan A, Zerin F, Zamila M, Parvez F, et al. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep. 2020;10:14659.","journal-title":"Sci Rep"},{"key":"1816_CR121","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","volume":"69","author":"X Sun","year":"2020","unstructured":"Sun X, Han F, Lu Q, Li X, Ren D, Zhang J, et al. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice. Diabetes. 2020;69:1292\u2013305.","journal-title":"Diabetes"},{"key":"1816_CR122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2019.10.411","volume":"146","author":"S Anavi","year":"2020","unstructured":"Anavi S, Tirosh O. iNOS as a metabolic enzyme under stress conditions. Free Radic Biol Med. 2020;146:16\u201335.","journal-title":"Free Radic Biol Med"},{"key":"1816_CR123","first-page":"353","volume":"55","author":"MM Liu","year":"2020","unstructured":"Liu MM, Shi J. Physiological and pathological effects of nitric oxide and nitric oxide synthase in oral cavity. Zhonghua Kou Qiang Yi Xue Za Zhi. 2020;55:353\u20136.","journal-title":"Zhonghua Kou Qiang Yi Xue Za Zhi"},{"key":"1816_CR124","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jinorgbio.2014.06.011","volume":"139","author":"V Berka","year":"2014","unstructured":"Berka V, Liu W, Wu G, Tsai AL. Comparison of oxygen-induced radical intermediates in iNOS oxygenase domain with those from nNOS and eNOS. J Inorg Biochem. 2014;139:93\u2013105.","journal-title":"J Inorg Biochem"},{"key":"1816_CR125","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jcp.21495","volume":"217","author":"F Wu","year":"2008","unstructured":"Wu F, Tyml K, Wilson JX. iNOS expression requires NADPH oxidase-dependent redox signaling in microvascular endothelial cells. J Cell Physiol. 2008;217:207\u201314.","journal-title":"J Cell Physiol"},{"key":"1816_CR126","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1089\/ars.2019.7915","volume":"33","author":"M Chocry","year":"2020","unstructured":"Chocry M, Leloup L. The NADPH oxidase family and its inhibitors. Antioxid Redox Signal. 2020;33:332\u201353.","journal-title":"Antioxid Redox Signal"},{"key":"1816_CR127","doi-asserted-by":"publisher","first-page":"7161592","DOI":"10.1155\/2018\/7161592","volume":"2018","author":"X Liu","year":"2018","unstructured":"Liu X, Zhu Q, Zhang M, Yin T, Xu R, Xiao W, et al. Isoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2\/HO-1 pathway. Oxid Med Cell Longev. 2018;2018:7161592.","journal-title":"Oxid Med Cell Longev"},{"key":"1816_CR128","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.18632\/aging.101526","volume":"10","author":"X Liu","year":"2018","unstructured":"Liu X, Lin X, Zhang S, Guo C, Li J, Mi Y, et al. Lycopene ameliorates oxidative stress in the aging chicken ovary via activation of Nrf2\/HO-1 pathway. Aging. 2018;10:2016\u201336.","journal-title":"Aging"},{"key":"1816_CR129","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/molecules24183231","volume":"24","author":"L Hu","year":"2019","unstructured":"Hu L, Tian K, Zhang T, Fan CH, Zhou P, Zeng D, et al. Cyanate induces oxidative stress injury and abnormal lipid metabolism in liver through Nrf2\/HO-1. Molecules. 2019;24:3231.","journal-title":"Molecules"},{"key":"1816_CR130","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fendo.2019.00187","volume":"10","author":"M Kitada","year":"2019","unstructured":"Kitada M, Ogura Y, Monno I, Koya D. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Front Endocrinol. 2019;10:187.","journal-title":"Front Endocrinol"},{"key":"1816_CR131","doi-asserted-by":"crossref","first-page":"3159801","DOI":"10.1155\/2018\/3159801","volume":"2018","author":"B Zhang","year":"2018","unstructured":"Zhang B, Zhai M, Li B, Liu Z, Li K, Jiang L, et al. Honokiol ameliorates myocardial ischemia\/reperfusion injury in type 1 diabetic rats by reducing oxidative stress and apoptosis through activating the SIRT1-Nrf2 signaling pathway. Oxid Med Cell Longev. 2018;2018:3159801.","journal-title":"Oxid Med Cell Longev"},{"key":"1816_CR132","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1111\/jcmm.15725","volume":"24","author":"BC Ren","year":"2020","unstructured":"Ren BC, Zhang YF, Liu SS, Cheng XJ, Yang X, Cui XG, et al. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. J Cell Mol Med. 2020;24:12355\u201367.","journal-title":"J Cell Mol Med"},{"key":"1816_CR133","doi-asserted-by":"publisher","first-page":"8534","DOI":"10.1002\/jcb.28141","volume":"120","author":"JW Kim","year":"2019","unstructured":"Kim JW, Lee YJ, You YH, Moon MK, Yoon KH, Ahn YB, et al. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem. 2019;120:8534\u201346.","journal-title":"J Cell Biochem"},{"key":"1816_CR134","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11010-020-03686-x","volume":"466","author":"HE Mohamed","year":"2020","unstructured":"Mohamed HE, Asker ME, Keshawy MM, Hasan RA, Mahmoud YK. Inhibition of tumor necrosis factor-\u03b1 enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance. Mol Cell Biochem. 2020;466:45\u201354.","journal-title":"Mol Cell Biochem"},{"key":"1816_CR135","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.redox.2015.06.019","volume":"6","author":"LO Klotz","year":"2015","unstructured":"Klotz LO, S\u00e1nchez-Ramos C, Prieto-Arroyo I, Urb\u00e1nek P, Steinbrenner H, Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol. 2015;6:51\u201372.","journal-title":"Redox Biol"},{"key":"1816_CR136","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/db19-0423","volume":"68","author":"M Ljubkovic","year":"2019","unstructured":"Ljubkovic M, Gressette M, Bulat C, Cavar M, Bakovic D, Fabijanic D, et al. Disturbed fatty acid oxidation, endoplasmic reticulum stress, and apoptosis in left ventricle of patients with type 2 diabetes. Diabetes. 2019;68:1924\u201333.","journal-title":"Diabetes"},{"key":"1816_CR137","doi-asserted-by":"publisher","first-page":"117138","DOI":"10.1016\/j.lfs.2019.117138","volume":"240","author":"ZW Yu","year":"2020","unstructured":"Yu ZW, Zhang J, Li X, Wang Y, Fu YH, Gao XY. A new research hot spot: the role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications. Life Sci. 2020;240:117138.","journal-title":"Life Sci"},{"key":"1816_CR138","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","volume":"50","author":"N Van Opdenbosch","year":"2019","unstructured":"Van Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease. Immunity. 2019;50:1352\u201364.","journal-title":"Immunity"},{"key":"1816_CR139","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/ijms22031177","volume":"22","author":"NN Trang","year":"2021","unstructured":"Trang NN, Chung CC, Lee TW, Cheng WL, Kao YH, Huang SY, et al. Empagliflozin and liraglutide differentially modulate cardiac metabolism in diabetic cardiomyopathy in rats. Int J Mol Sci. 2021;22:1177.","journal-title":"Int J Mol Sci"},{"key":"1816_CR140","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/febs.14186","volume":"285","author":"A Pe\u00f1a-Blanco","year":"2018","unstructured":"Pe\u00f1a-Blanco A, Garc\u00eda-S\u00e1ez AJ. Bax, Bak and beyond\u2014mitochondrial performance in apoptosis. Febs j. 2018;285:416\u201331.","journal-title":"Febs j"},{"key":"1816_CR141","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.1007\/s13277-016-5035-9","volume":"37","author":"Y Kiraz","year":"2016","unstructured":"Kiraz Y, Adan A, Yandim MK, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016;37:8471\u201386.","journal-title":"Tumour Biol"},{"key":"1816_CR142","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cyto.2014.08.004","volume":"71","author":"QL Wang","year":"2015","unstructured":"Wang QL, Zhao L, Feng N, Zhou P, Wu Q, Fan R, et al. Lacidipine attenuates TNF-\u03b1-induced cardiomyocyte apoptosis. Cytokine. 2015;71:60\u20135.","journal-title":"Cytokine"},{"key":"1816_CR143","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","volume":"109","author":"CC Yang","year":"2019","unstructured":"Yang CC, Chen YT, Wallace CG, Chen KH, Cheng BC, Sung PH, et al. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother. 2019;109:658\u201370.","journal-title":"Biomed Pharmacother"},{"key":"1816_CR144","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol. 2020;19:91.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR145","doi-asserted-by":"publisher","first-page":"24270","DOI":"10.18632\/aging.202143","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang J, Huang L, Shi X, Yang L, Hua F, Ma J, et al. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK\/NLRP3 inflammasome pathway. Aging. 2020;12:24270\u201387.","journal-title":"Aging"},{"key":"1816_CR146","doi-asserted-by":"publisher","first-page":"172797","DOI":"10.1016\/j.ejphar.2019.172797","volume":"867","author":"R Hu","year":"2020","unstructured":"Hu R, Wang MQ, Ni SH, Wang M, Liu LY, You HY, et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK\/NF-kappaB\/NLRP3 signaling pathway in AGEs-induced HUVECs. Eur J Pharmacol. 2020;867:172797.","journal-title":"Eur J Pharmacol"},{"key":"1816_CR147","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12906-019-2703-5","volume":"19","author":"C Ma","year":"2019","unstructured":"Ma C, Wang X, Xu T, Yu X, Zhang S, Liu S, et al. Qingkailing injection ameliorates cerebral ischemia-reperfusion injury and modulates the AMPK\/NLRP3 inflammasome signalling pathway. BMC Complement Altern Med. 2019;19:320.","journal-title":"BMC Complement Altern Med"},{"key":"1816_CR148","doi-asserted-by":"publisher","first-page":"116631","DOI":"10.1016\/j.lfs.2019.116631","volume":"233","author":"RC Yue","year":"2019","unstructured":"Yue RC, Lu SZ, Luo Y, Wang T, Liang H, Zeng J, et al. Calpain silencing alleviates myocardial ischemia-reperfusion injury through the NLRP3\/ASC\/Caspase-1 axis in mice. Life Sci. 2019;233:116631.","journal-title":"Life Sci"},{"key":"1816_CR149","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2015.00262","volume":"6","author":"BZ Shao","year":"2015","unstructured":"Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.","journal-title":"Front Pharmacol"},{"key":"1816_CR150","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42:245\u201354.","journal-title":"Trends Biochem Sci"},{"key":"1816_CR151","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.2147\/JIR.S308177","volume":"14","author":"N Ji","year":"2021","unstructured":"Ji N, Qi Z, Wang Y, Yang X, Yan Z, Li M, et al. Pyroptosis: a new regulating mechanism in cardiovascular disease. J Inflamm Res. 2021;14:2647\u201366.","journal-title":"J Inflamm Res"},{"key":"1816_CR152","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31:119\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1816_CR153","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10557-020-06978-y","volume":"34","author":"H Chen","year":"2020","unstructured":"Chen H, Tran D, Yang HC, Nylander S, Birnbaum Y, Ye Y. Dapagliflozin and ticagrelor have additive effects on the attenuation of the activation of the NLRP3 inflammasome and the progression of diabetic cardiomyopathy: an AMPK-mTOR interplay. Cardiovasc Drugs Ther. 2020;34:443\u201361.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1816_CR154","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1534-5807(04)00099-1","volume":"6","author":"B Levine","year":"2004","unstructured":"Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463\u201377.","journal-title":"Dev Cell"},{"key":"1816_CR155","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728\u201341.","journal-title":"Cell"},{"key":"1816_CR156","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrcardio.2017.35","volume":"14","author":"LMD Delbridge","year":"2017","unstructured":"Delbridge LMD, Mellor KM, Taylor DJ, Gottlieb RA. Myocardial stress and autophagy: mechanisms and potential therapies. Nat Rev Cardiol. 2017;14:412\u201325.","journal-title":"Nat Rev Cardiol"},{"key":"1816_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-physiol-021317-121427","volume":"80","author":"S Sciarretta","year":"2018","unstructured":"Sciarretta S, Maejima Y, Zablocki D, Sadoshima J. The role of autophagy in the heart. Annu Rev Physiol. 2018;80:1\u201326.","journal-title":"Annu Rev Physiol"},{"key":"1816_CR158","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1194\/jlr.M090969","volume":"60","author":"Y Li","year":"2019","unstructured":"Li Y, Yang P, Zhao L, Chen Y, Zhang X, Zeng S, et al. CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway. J Lipid Res. 2019;60:844\u201355.","journal-title":"J Lipid Res"},{"key":"1816_CR159","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214\u201326.","journal-title":"Mol Cell"},{"key":"1816_CR160","doi-asserted-by":"publisher","first-page":"109368","DOI":"10.1016\/j.cbi.2021.109368","volume":"335","author":"HH Arab","year":"2021","unstructured":"Arab HH, Al-Shorbagy MY, Saad MA. Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: targeting AMPK\/mTOR, HMGB1\/RAGE and Nrf2\/HO-1 pathways. Chem Biol Interact. 2021;335:109368.","journal-title":"Chem Biol Interact"},{"key":"1816_CR161","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132\u201341.","journal-title":"Nat Cell Biol"},{"key":"1816_CR162","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","volume":"13","author":"K Jiang","year":"2022","unstructured":"Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13:336\u201359.","journal-title":"Protein Cell"},{"key":"1816_CR163","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"1816_CR164","doi-asserted-by":"publisher","first-page":"113606","DOI":"10.1016\/j.biopha.2022.113606","volume":"154","author":"R Deng","year":"2022","unstructured":"Deng R, Jiang K, Chen F, Miao Y, Lu Y, Su F, et al. Novel cardioprotective mechanism for empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia. Biomed Pharmacother. 2022;154:113606.","journal-title":"Biomed Pharmacother"},{"key":"1816_CR165","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2174\/1566524015666150921105453","volume":"15","author":"WS Lee","year":"2015","unstructured":"Lee WS, Yoo WH, Chae HJ. ER stress and autophagy. Curr Mol Med. 2015;15:735\u201345.","journal-title":"Curr Mol Med"},{"key":"1816_CR166","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lfs.2019.04.022","volume":"226","author":"IM Ibrahim","year":"2019","unstructured":"Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: a cell\u2019s response to stress. Life Sci. 2019;226:156\u201363.","journal-title":"Life Sci"},{"key":"1816_CR167","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri.2016.62","volume":"16","author":"J Grootjans","year":"2016","unstructured":"Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. Nat Rev Immunol. 2016;16:469\u201384.","journal-title":"Nat Rev Immunol"},{"key":"1816_CR168","doi-asserted-by":"publisher","first-page":"13739","DOI":"10.1080\/21655979.2022.2080413","volume":"13","author":"LD Wu","year":"2022","unstructured":"Wu LD, Liu Y, Li F, Chen JY, Zhang J, Qian LL, et al. Glucose fluctuation promotes cardiomyocyte apoptosis by triggering endoplasmic reticulum (ER) stress signaling pathway in vivo and in vitro. Bioengineered. 2022;13:13739\u201351.","journal-title":"Bioengineered"},{"key":"1816_CR169","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","volume":"9","author":"H Hu","year":"2018","unstructured":"Hu H, Tian M, Ding C, Yu S. The C\/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Front Immunol. 2018;9:3083.","journal-title":"Front Immunol"},{"key":"1816_CR170","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2015.02.004","volume":"33","author":"O Kepp","year":"2015","unstructured":"Kepp O, Semeraro M, Pedro JMBS, Bloy N, Buque A, Huang X, et al. eIF2\u03b1 phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol. 2015;33:86\u201392.","journal-title":"Semin Cancer Biol"},{"key":"1816_CR171","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro R, Munoz-Pinedo C. Cell death induced by endoplasmic reticulum stress. FEBS J. 2016;283:2640\u201352.","journal-title":"FEBS J"},{"key":"1816_CR172","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","volume":"43","author":"FF Ren","year":"2022","unstructured":"Ren FF, Xie ZY, Jiang YN, Guan X, Chen QY, Lai TF, et al. Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2022;43:1721\u201332.","journal-title":"Acta Pharmacol Sin"},{"key":"1816_CR173","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/1061186X.2022.2064479","volume":"30","author":"CC Wang","year":"2022","unstructured":"Wang CC, Li Y, Qian XQ, Zhao H, Wang D, Zuo GX, et al. Empagliflozin alleviates myocardial I\/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK\/ATF4\/Beclin1 pathway. J Drug Target. 2022;30:858\u201372.","journal-title":"J Drug Target"},{"key":"1816_CR174","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","volume":"95","author":"WT Chang","year":"2021","unstructured":"Chang WT, Lin YW, Ho CH, Chen ZC, Liu PY, Shih JY. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. Arch Toxicol. 2021;95:659\u201371.","journal-title":"Arch Toxicol"},{"key":"1816_CR175","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/ijms21010190","volume":"21","author":"K Hosokawa","year":"2019","unstructured":"Hosokawa K, Takata T, Sugihara T, Matono T, Koda M, Kanda T, et al. Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules. Int J Mol Sci. 2019;21:190.","journal-title":"Int J Mol Sci"},{"key":"1816_CR176","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-018-0108-7","volume":"16","author":"WHW Tang","year":"2019","unstructured":"Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16:137\u201354.","journal-title":"Nat Rev Cardiol"},{"key":"1816_CR177","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/nu10020203","volume":"10","author":"H Hug","year":"2018","unstructured":"Hug H, Mohajeri MH, La Fata G. Toll-like receptors: regulators of the immune response in the human gut. Nutrients. 2018;10:203.","journal-title":"Nutrients"},{"key":"1816_CR178","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","volume":"56","author":"PD Cani","year":"2007","unstructured":"Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761\u201372.","journal-title":"Diabetes"},{"key":"1816_CR179","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrcardio.2016.183","volume":"14","author":"AL Jonsson","year":"2017","unstructured":"Jonsson AL, B\u00e4ckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14:79\u201387.","journal-title":"Nat Rev Cardiol"},{"key":"1816_CR180","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.trsl.2020.08.007","volume":"228","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Transl Res. 2021;228:109\u201325.","journal-title":"Transl Res"},{"key":"1816_CR181","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","volume":"17","author":"DM Lee","year":"2018","unstructured":"Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR182","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","volume":"63","author":"NR Shin","year":"2014","unstructured":"Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63:727\u201335.","journal-title":"Gut."},{"key":"1816_CR183","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/CIRCULATIONAHA.115.019645","volume":"133","author":"J Li","year":"2016","unstructured":"Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe-\/- mice. Circulation. 2016;133:2434\u201346.","journal-title":"Circulation"},{"key":"1816_CR184","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/s41467-020-18262-6","volume":"11","author":"W Yang","year":"2020","unstructured":"Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, et al. Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020;11:4457.","journal-title":"Nat Commun"},{"key":"1816_CR185","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz039","author":"SS Ghosh","year":"2020","unstructured":"Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020. https:\/\/doi.org\/10.1210\/jendso\/bvz039.","journal-title":"J Endocr Soc"},{"key":"1816_CR186","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/nu14173531","volume":"14","author":"S Hata","year":"2022","unstructured":"Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, et al. Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db\/db mice. Nutrients. 2022;14:3531.","journal-title":"Nutrients"},{"key":"1816_CR187","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/clinem\/dgac210","volume":"107","author":"X Deng","year":"2022","unstructured":"Deng X, Zhang C, Wang P, Wei W, Shi X, Wang P, et al. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab. 2022;107:1888\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"1816_CR188","doi-asserted-by":"publisher","first-page":"111649","DOI":"10.1016\/j.biopha.2021.111649","volume":"139","author":"T Nozu","year":"2021","unstructured":"Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T. Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome. Biomed Pharmacother. 2021;139:111649.","journal-title":"Biomed Pharmacother"},{"key":"1816_CR189","doi-asserted-by":"publisher","first-page":"e15092","DOI":"10.14814\/phy2.15092","volume":"9","author":"HJ Ho","year":"2021","unstructured":"Ho HJ, Kikuchi K, Oikawa D, Watanabe S, Kanemitsu Y, Saigusa D, et al. SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure. Physiol Rep. 2021;9:e15092.","journal-title":"Physiol Rep"},{"key":"1816_CR190","doi-asserted-by":"publisher","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","volume":"315","author":"E Mishima","year":"2018","unstructured":"Mishima E, Fukuda S, Kanemitsu Y, Saigusa D, Mukawa C, Asaji K, et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am J Physiol Renal Physiol. 2018;315:F824\u201333.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1816_CR191","doi-asserted-by":"publisher","first-page":"e89977","DOI":"10.1371\/journal.pone.0089977","volume":"9","author":"PV R\u00f6der","year":"2014","unstructured":"R\u00f6der PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS ONE. 2014;9:e89977.","journal-title":"PLoS ONE"},{"key":"1816_CR192","doi-asserted-by":"publisher","first-page":"154936","DOI":"10.1016\/j.metabol.2021.154936","volume":"127","author":"R Marfella","year":"2022","unstructured":"Marfella R, D\u2019Onofrio N, Trotta MC, Sardu C, Scisciola L, Amarelli C, et al. Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127:154936.","journal-title":"Metabolism"},{"key":"1816_CR193","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation"},{"key":"1816_CR194","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421\u201332.","journal-title":"Eur Heart J"},{"key":"1816_CR195","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-021-01264-z","volume":"20","author":"AC Sposito","year":"2021","unstructured":"Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, et al. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021;20:74.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR196","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12933-022-01607-4","volume":"21","author":"L Leccisotti","year":"2022","unstructured":"Leccisotti L, Cinti F, Sorice GP, D\u2019Amario D, Lorusso M, Guzzardi MA, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR197","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","volume":"16","author":"C Ott","year":"2017","unstructured":"Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16:26.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR198","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","volume":"21","author":"P Paolisso","year":"2022","unstructured":"Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21:77.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR199","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstrale","year":"2014","unstructured":"Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691\u2013700.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1816_CR200","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.2433","volume":"24","author":"K McDowell","year":"2022","unstructured":"McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, de Boer RA, et al. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022;24:1066\u201376.","journal-title":"Eur J Heart Fail"},{"key":"1816_CR201","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dom.12439","volume":"17","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Trujillo A, Vijapurkar U, Damaraju CV, Meininger G. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR202","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.diabet.2019.11.005","volume":"46","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Herrema H, Davids M, Kramer MHH, Nieuwdorp M, van Raalte DH. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. Diabetes Metab. 2020;46:164\u20138.","journal-title":"Diabetes Metab"},{"key":"1816_CR203","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","volume":"19","author":"WJ Li","year":"2020","unstructured":"Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:130.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR204","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","volume":"21","author":"HM Salah","year":"2022","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21:20.","journal-title":"Cardiovasc Diabetol"},{"key":"1816_CR205","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-020-01209-y","volume":"20","author":"YW Yu","year":"2021","unstructured":"Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20:25.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 2","key":"1816_CR206","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.2337\/dcS15-3005","volume":"39","author":"JP Wilding","year":"2016","unstructured":"Wilding JP, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors\/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(Suppl 2):S154\u201364.","journal-title":"Diabetes Care"},{"key":"1816_CR207","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2337\/dc18-2207","volume":"42","author":"PI Georgianos","year":"2019","unstructured":"Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693\u2013700.","journal-title":"Diabetes Care"},{"key":"1816_CR208","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21:434\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR209","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1816_CR210","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687\u201393.","journal-title":"Diabetes Care"},{"key":"1816_CR211","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"CJ Bailey","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22:39\u201352.","journal-title":"Curr Diab Rep"},{"key":"1816_CR212","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneph.2016.159","volume":"12","author":"K Hahn","year":"2016","unstructured":"Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711\u20132.","journal-title":"Nat Rev Nephrol"},{"key":"1816_CR213","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1177\/1060028016657839","volume":"50","author":"RM Rivosecchi","year":"2016","unstructured":"Rivosecchi RM, Kellum JA, Dasta JF, Armahizer MJ, Bolesta S, Buckley MS, et al. Drug class combination-associated acute kidney injury. Ann Pharmacother. 2016;50:953\u201372.","journal-title":"Ann Pharmacother"},{"key":"1816_CR214","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1816_CR215","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11914-020-00609-z","volume":"18","author":"K Jackson","year":"2020","unstructured":"Jackson K, Moseley KF. Diabetes and bone fragility: SGLT2 inhibitor use in the context of renal and cardiovascular benefits. Curr Osteoporos Rep. 2020;18:439\u201348.","journal-title":"Curr Osteoporos Rep"},{"key":"1816_CR216","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","volume":"43","author":"F Zannad","year":"2022","unstructured":"Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43:4991\u20135002.","journal-title":"Eur Heart J"},{"key":"1816_CR217","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","volume":"36","author":"E O'Meara","year":"2020","unstructured":"O\u2019Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol. 2020;36:159\u201369.","journal-title":"Can J Cardiol"},{"key":"1816_CR218","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37:531\u201346.","journal-title":"Can J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T07:33:15Z","timestamp":1729236795000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":218,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01816-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}